Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 14/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.59 |
| ▸ | PI4KA | P42356 | 1/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.59 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640041 | 0.82 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL2060472 | 0.81 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL5731732 | 0.80 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL26628550 | 0.77 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL4236128 | 0.77 | YTHDC1 (0.71) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7205020 | 0.76 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7204756 | 0.76 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7209247 | 0.76 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7209460 | 0.76 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7204064 | 0.76 | ADORA2A (0.76) | CTSLPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-11-28 | — | — | US | disclosed |
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2776439-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-04 | — | — | EP | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| WO-2013068438-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN R&D IRELAND (IE) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | PNP, ADA, HPRT1 | CTSL 1961/4885PDE4A 193/4885PDE4B 245/4885 |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | PNP, HPRT1, TYMP | CTSL 2116/4885PDE4A 238/4885PDE4B 281/4885 |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | CTSL 1961/4885PDE4A 193/4885PDE4B 245/4885 |
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | CTSL 1961/4885PDE4A 193/4885PDE4B 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.